Clinical Trials Browser

Interventional × Small Cell Lung Carcinoma × Immune Checkpoint Inhibitors × Clear all

Small Cell Lung Carcinoma

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4 Not yet recruiting

31 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03994744 2019-08-28

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Phase 2 Unknown

68 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC